FGL Peptide vs P21 (CNTF-Derived Peptide)
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, FGL Peptide or P21 (CNTF-Derived Peptide)?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between FGL Peptide and P21 (CNTF-Derived Peptide)?
FGL targets NCAM-FGFR1 signaling for synaptic plasticity (with oncogenic risk); P21 is a CDKN1A fragment targeting neurogenesis via a different pathway - both are preclinical-only with no clear development path.
Evidence Comparison
FGL peptide: rodent-only data targeting NCAM/FGFR1 with cognitive enhancement signals, but FGFR1 is a known oncogene creating a fundamental safety concern. P21 peptide: CDKN1A-derived fragment, rodent cognitive data, single research group. Neither has human data; both carry mechanistic safety flags.
Evidence Context Favoring FGL Peptide
NCAM/FGFR1 mechanistic research in synaptic plasticity models, with explicit oncogene risk acknowledgment.
Evidence Context Favoring P21 (CNTF-Derived Peptide)
CDKN1A-mediated neurogenesis research; P21 avoids the FGFR1 oncogene concern but has equally limited evidence.
Side-by-Side Snapshot
| Evidence grade | FGL Peptide: Level D P21 (CNTF-Derived Peptide): Level D |
|---|---|
| Research status | FGL Peptide: Preclinical P21 (CNTF-Derived Peptide): Preclinical |
| Primary category | FGL Peptide: Cognitive & Nootropic P21 (CNTF-Derived Peptide): Cognitive & Nootropic |
| Cited studies | FGL Peptide: 3 P21 (CNTF-Derived Peptide): 2 |